Substituted pyridines as inhibitors of DNMT1
US10975056B2 · kind B2 · utility
Assignees
Inventors
- Nicholas D. Adams
- Andrew B. Benowitz
- María Lourdes Rueda Benede
- Karen Anderson Evans
- David T. FOSBENNER
- Bryan Wayne King
- Mei Li
- Juan Luengo
- William Henry Miller
- Alexander Joseph Reif
- Stuart Paul Romeril
- Stanley J. Schmidt
- Roger John Butlin
- Kristin M. Goldberg
- Allan Jordan
- Christopher Stephen KERSHAW
- Ali Raoof
- Bohdan Waszkowycz
Key dates
| Filing date | Jun 13, 2017 |
| Grant date | Apr 13, 2021 |
| Priority date | — |
| Expiry date | Jun 13, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.